[{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Bisantrene","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ Race Oncology"}]

Find Clinical Drug Pipeline Developments & Deals by Ardena

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).

                          Brand Name : RC220

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 12, 2023

                          Lead Product(s) : Bisantrene

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Race Oncology

                          Deal Size : $1.0 million

                          Deal Type : Agreement

                          blank